The estimated overall survival rate for patients receiving Gleevec was 88% when considering deaths from all causes.
在进行死因分析时，接受伊马替尼治疗的患者的总体生存率为88%。
Cumulative best responses to Gleevec treatment improved dramatically between the first and sixth years of treatment.
在治疗的第一年到第六年之间，伊马替尼治疗的累积最佳应答率显著提高。
The much touted anti-leukemia drug Gleevec here appears as the hero of modern, genetics-based cancer therapy, a “rationally designed” drug specifically directed against a known cancer gene.
格列卫（Gleevec）这种广为宣传的抗白血病药物在这里成了现代基因癌症治疗的英雄，是一种“理性设计”出来专门针对特定肿瘤基因的药物。
There is already a targeted treatment for this disease. Gleevec, probably the most remarkable anti-cancer drug of the past decade, disables the protein encoded by another fused gene, BCR-ABL.
现在对这种病已有针对性疗法，Gleevec大体是过去十年中效果最显著的药物，它能使另一融合基因BCR-ABL的编码蛋白失去活性。
Some patients have suffered relapses due to acquired point mutations in KIT, which prevents Gleevec from binding to the protein.
一些肿瘤复发的病人由于KIT发生了点突变，这阻止了Gleevec结合蛋白激酶。
Recent research shows that a new targeting therapeutic agent, SU11248, can prolong the survival time of the patients with GISTs who were resistant to Gleevec therapy.
最新研究表明新的靶向治疗药物SU11248对格列卫耐药的患者有延长生存期的作用。
Recent research shows that a new targeting therapeutic agent, SU11248, can prolong the survival time of the patients with GISTs who were resistant to Gleevec therapy.
最新研究表明新的靶向治疗药物SU11248对格列卫耐药的患者有延长生存期的作用。
应用推荐